Stimulation of Lung Innate Immunity Protects against Lethal Pneumococcal Pneumonia in Mice

The lungs are a common site of serious infection in both healthy and immunocompromised subjects, and the most likely route of delivery of a bioterror agent. Since the airway epithelium shows great structural plasticity in response to inflammatory stimuli, we hypothesized it might also show functiona...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory and critical care medicine Vol. 177; no. 12; pp. 1322 - 1330
Main Authors Clement, Cecilia G, Evans, Scott E, Evans, Christopher M, Hawke, David, Kobayashi, Ryuji, Reynolds, Paul R, Moghaddam, Seyed J, Scott, Brenton L, Melicoff, Ernestina, Adachi, Roberto, Dickey, Burton F, Tuvim, Michael J
Format Journal Article
LanguageEnglish
Published New York, NY Am Thoracic Soc 15.06.2008
American Lung Association
American Thoracic Society
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The lungs are a common site of serious infection in both healthy and immunocompromised subjects, and the most likely route of delivery of a bioterror agent. Since the airway epithelium shows great structural plasticity in response to inflammatory stimuli, we hypothesized it might also show functional plasticity. To test the inducibility of lung defenses against bacterial challenge. Mice were treated with an aerosolized lysate of ultraviolet-killed nontypeable (unencapsulated) Haemophilus influenzae (NTHi), then challenged with a lethal dose of live Streptococcus pneumoniae (Spn) delivered by aerosol. Treatment with the NTHi lysate induced complete protection against challenge with a lethal dose of Spn if treatment preceded challenge by 4 to 24 hours. Lesser levels of protection occurred at shorter (83% at 2 h) and longer (83% at 48-72 h) intervals between treatment and challenge. There was also some protection when treatment was given 2 hours after challenge (survival increased from 14 to 57%), but not 24 hours after challenge. Protection did not depend on recruited neutrophils or resident mast cells and alveolar macrophages. Protection was specific to the airway route of infection, correlated in magnitude and time with rapid bacterial killing within the lungs, and was associated with increases of multiple antimicrobial polypeptides in lung lining fluid. We infer that protection derives from stimulation of local innate immune mechanisms, and that activated lung epithelium is the most likely cellular effector of this response. Augmentation of innate antimicrobial defenses of the lungs might have therapeutic value.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org
Conflict of Interest Statement: C.G.C., and B.F.D., and M.J.T. are the inventors of the subject matter disclosed in the patent application “Compositions and Methods for Stimulation of Lung Innate Immunity” filed by the Board of Regents of the University of Texas System. S.E.E. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. C.M.E. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. D.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.K. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. P.R.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.J.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. B.L.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. E.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.A. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.
Originally Published in Press as DOI: 10.1164/rccm.200607-1038OC on April 3, 2008
Supported by the George and Barbara Bush Endowment for Innovative Cancer Research and the Odyssey Fellowship Program from the University of Texas M.D. Anderson Cancer Center, and grants HL072984, CA105352, and CA016672 from the National Institutes of Health.
Correspondence and requests for reprints should be addressed to Burton F. Dickey, M.D., Department of Pulmonary Medicine, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009. E-mail: bdickey@mdanderson.org
ISSN:1073-449X
1535-4970
1535-4970
DOI:10.1164/rccm.200607-1038OC